Literature DB >> 15605425

Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling.

Antonella Zucchetto1, Paolo Sonego, Massimo Degan, Riccardo Bomben, Michele Dal Bo, Stefania Russo, Vincenza Attadia, Maurizio Rupolo, Francesco Buccisano, Maria Ilaria Del Principe, Giovanni Del Poeta, Carlo Pucillo, Alfonso Colombatti, Renato Campanini, Valter Gattei.   

Abstract

With the aim of identifying the immunophenotypic profile of B-cell chronic lymphocytic leukemia (B-CLL) subsets with different prognosis, we investigated by flow cytometry the expression of 36 surface antigens in 123 cases, all with survivals. By analyzing results with unsupervised (hierarchical and K-means clustering) algorithms, three distinct immunophenotypic groups (I, II, and III) were identified, group I (51/123) with longer survivals, as compared to the group II (36/123) and III (36/123). The immunophenotypic signatures of these groups, as determined by applying the nearest Shrunken centroids method as class predictor, were characterized by the coordinated and differential expression of 12 surface markers, that is, group I: above-average expression of CD62L, CD54, CD49c, and CD25, below-average expression of CD38; group II: above-average expression of CD38, CD49d, CD29, and CD49e; and group III: below-average expression of the above markers, overexpression of CD23, CD20, SmIg, and CD79b. As opposed to groups II-III, group I B-CLLs lacked expression of ZAP-70 and activation-induced cytidine deaminase in the majority of cases, while more frequently had mutated IgV(H) genes and IgV(H) mutations consistent with antigen-driven selection. Our findings contribute to improve the immunophenotypical identification of disease subsets with different prognosis and suggest a set of surface antigens to be employed as prognosticators in routine diagnostic/prognostic procedures. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15605425     DOI: 10.1002/jcp.20269

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34(+) hemopoietic progenitors cells.

Authors:  F M Rossi; A Zucchetto; E Tissino; M Dal Bo; R Bomben; C Caldana; F Pozzo; G Del Poeta; D Rossi; G Gaidano; V Gattei
Journal:  Leukemia       Date:  2013-11-08       Impact factor: 11.528

2.  CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.

Authors:  Erika Tissino; Federico Pozzo; Dania Benedetti; Chiara Caldana; Tamara Bittolo; Francesca Maria Rossi; Riccardo Bomben; Paola Nanni; Hillarj Chivilò; Ilaria Cattarossi; Eva Zaina; Kevin Norris; Jerry Polesel; Massimo Gentile; Giovanni Tripepi; Riccardo Moia; Enrico Santinelli; Idanna Innocenti; Jacopo Olivieri; Giovanni D'Arena; Luca Laurenti; Francesco Zaja; Gabriele Pozzato; Annalisa Chiarenza; Francesco Di Raimondo; Davide Rossi; Chris Pepper; Tanja Nicole Hartmann; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei; Antonella Zucchetto
Journal:  Blood       Date:  2020-04-09       Impact factor: 22.113

Review 3.  Data analysis in flow cytometry: the future just started.

Authors:  Enrico Lugli; Mario Roederer; Andrea Cossarizza
Journal:  Cytometry A       Date:  2010-07       Impact factor: 4.355

4.  CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.

Authors:  Paolo Strati; Sameer A Parikh; Kari G Chaffee; Sara J Achenbach; Susan L Slager; Timothy G Call; Wei Ding; Diane F Jelinek; Curtis A Hanson; Neil E Kay; Tait D Shanafelt
Journal:  Br J Haematol       Date:  2017-04-07       Impact factor: 6.998

5.  CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.

Authors:  Tait D Shanafelt; Susan M Geyer; Nancy D Bone; Renee C Tschumper; Tom E Witzig; Greg S Nowakowski; Clive S Zent; Tim G Call; Betsy Laplant; Gordon W Dewald; Diane F Jelinek; Neil E Kay
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

6.  Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance.

Authors:  Antonella Zucchetto; Paolo Sonego; Massimo Degan; Riccardo Bomben; Michele Dal Bo; Pietro Bulian; Dania Benedetti; Maurizio Rupolo; Giovanni Del Poeta; Renato Campanini; Valter Gattei
Journal:  J Transl Med       Date:  2006-03-01       Impact factor: 5.531

7.  Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis.

Authors:  Chien-Yuan Chen; Wen-Chien Chou; Woei Tsay; Jih-Luh Tang; Ming Yao; Sheng-Yi Huang; Hwei-Fang Tien
Journal:  BMC Cancer       Date:  2013-03-08       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.